Project Details
Description
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction of 40%
| Status | Active |
|---|---|
| Effective start/end date | 7/1/20 → 7/31/24 |
Funding
- BAYER HEALTHCARE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.